Metabolic alterations associated with sacubitril/valsartan treatment: a systematic review and meta-analysis
{{output}}
Background: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, influences metabolic pathways, potentially altering glycemic indices and lipid profiles, but evidence remains scattered. Therefore, we aimed to quant... ...
